desmopressin acetate + letrozole

Desmopressin acetate + letrozole is a combination of two pharmaceutical agents, each with distinct mechanisms of action. Desmopressin acetate is a synthetic analog of vasopressin (antidiuretic hormone) that acts primarily on renal V2 receptors to reduce urine production and manage conditions such as central diabetes insipidus, nocturia, hemophilia A, and von Willebrand’s disease (Type I)[6][7][10]. Letrozole is a non-steroidal aromatase inhibitor that blocks the conversion of androgens to estrogens by inhibiting the enzyme aromatase (CYP19A1), thereby reducing estrogen levels in the body[2][8]. It is primarily used in postmenopausal women for hormone receptor-positive breast cancer. The combination has been reported in case studies for specific clinical scenarios but does not have an established or approved fixed-dose formulation or unique brand name[1].

Other names

desmopressin acetate and letrozole